Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

US8912139B2 · kind B2 · utility

Assignee

• The Board of Trustees of the University of Illinois · US

Inventors

• Yulia A. Komarova · Chicago, US
• Uzma Saqib · Chicago, US
• Stephen M. Vogel · Boulder, US
• Asrar Malik · Chicago, US

Key dates

• Filing date: Mar 31, 2014
• Grant date: Dec 16, 2014
• Expiry date: Mar 31, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.